Renal Cell Carcinoma Treatment Pipeline

Share this content:
Renal Cell Carcinoma Treatment Pipeline
Renal Cell Carcinoma Treatment Pipeline

In 2011, an estimated 61,000 patients in the United States were diagnosed with cancer of the kidney, with approximately 60% of the cases diagnosed in men.1 The disease caused slightly more than 13,000 deaths. The incidence of renal cell carcinoma (RCC) is increasing, more than doubling between 1950 and 2001, some of which can be explained by better detection with modern imaging techniques, but other reasons are not fully understood.2,3 Approximately 85% of RCC are of the clear cell type.2

The Treatment Landscape of RCC, Past and Present
Small renal tumors are amenable to surgical resection by partial or radical nephrectomy, or in some cases, less invasive techniques, with long-term survival achieved in 80%–95% of patients.2 Even locally invasive disease can be successfully managed in about 65% of cases. Historically, cytotoxic chemotherapy for advanced (stage IV) RCC produced responses in fewer than 10% of patients.4 Standard therapy for advanced RCC involves cytoreductive nephrectomy, if possible. Unlike other metastatic malignancies, resection of the primary RCC tumor is associated with improved survival.2 This observation led to investigations of immune mechanisms of tumorigenesis and treatment in the 1990s. It is now understood that RCC impairs T-cell mediated tumor immunity.5 High-dose aldesleukin (interleukin-2, IL-2) produced complete responses (some lasting one to three years) and an overall response rate of 28%, but toxicity is high. It still is a valid option in certain populations with low-volume disease and good performance status.5,6

A retrospective review of various trials with interferon-alfa (INF-α) found the median overall survival (OS) to be about 13 months.7 Based on these observations, INF-α was used as the control group for many of the Phase 3 clinical trials of targeted agents that began about ten years ago.

Since that time, seven targeted therapies have been approved by the FDA for advanced RCC:

     1. Axitinib (inhibitor of VEGFR-1, -2 and -3), 2012
     2. Bevacizumab (inhibitor of VEGF) with IFN-α, 2009
     3. Everolimus (inhibitor of mTOR), 2009
     4. Panzopanib (RTKI for VEGFR and PDGFR), 2009
     5. Sorafenib (RTKI for VEGF), PDGF and BRAF), 2005
     6. Sunitinib (RTKI for PDGF and VEGF), 2006
     7. Temsirolimus (mTOR inhibitor), 2007
[mTOR=inhibitor of mammalian target of rapamycin; PDGF=platelet-derived growth factor; RTKI=receptor tyrosine kinase inhibitor; VEGFR=vascular endothelial growth factor; VEGFR=VEGF receptor]

Page 1 of 5

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs